4.5 Article

Mechanism of 53BP1 activity regulation by RNA-binding TIRR and a designer protein

Journal

NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 25, Issue 7, Pages 591-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41594-018-0083-z

Keywords

-

Funding

  1. US Department of Energy, Office of Biological and Environmental Research [DE-AC02-06CH11357]
  2. NIH [R01 CA132878, R01 GM116829, P50 CA 136393, R01 CA208244, R01CA142698]
  3. DoD [W81XWH-15-0564/OC140632, W81XWH-16-1-0391]
  4. Leukemia and Lymphoma Society Scholar grant
  5. Claudia Adams Barr Program in Innovative Basic Cancer Research
  6. Ovarian Cancer Research Fund Alliance
  7. Mayo Clinic Cancer Center Fraternal Order of Eagles Funds
  8. Cancer Research UK Career Development Fellowship [C52690/A19270]
  9. Cancer Research UK [19270] Funding Source: researchfish
  10. NATIONAL CANCER INSTITUTE [R01CA132878, P50CA136393, R01CA142698, R01CA208244] Funding Source: NIH RePORTER
  11. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM116829] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Dynamic protein interaction networks such as DNA double-strand break (DSB) signaling are modulated by post-translational modifications. The DNA repair factor 53BP1 is a rare example of a protein whose post-translational modification-binding function can be switched on and off. 53BP1 is recruited to DSBs by recognizing histone lysine methylation within chromatin, an activity directly inhibited by the 53BP1-binding protein TIRR. X-ray crystal structures of TIRR and a designer protein bound to 53BP1 now reveal a unique regulatory mechanism in which an intricate binding area centered on an essential TIRR arginine residue blocks the methylated-chromatin-binding surface of 53BP1. A 53BP1 separation-of-function mutation that abolishes TIRR-mediated regulation in cells renders 53BP1 hyperactive in response to DSBs, highlighting the key inhibitory function of TIRR. This 53BP1 inhibition is relieved by TIRR-interacting RNA molecules, providing proof-of-principle of RNA-triggered 53BP1 recruitment to DSBs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

TIRR inhibits the 53BP1-p53 complex to alter cell-fate programs

Nishita Parnandi, Veronic Rendo, Gaofeng Cui, Maria Victoria Botuyan, Michaela Remisova, Huy Nguyen, Pascal Drane, Rameen Beroukhim, Matthias Altmeyer, Georges Mer, Dipanjan Chowdhury

Summary: TIRR inhibits the formation of the 53BP1-p53 complex by preventing the recruitment of 53BP1 to DSBs, leading to aberrant p53 activity and affecting p53-mediated cell-fate programs.

MOLECULAR CELL (2021)

Article Biochemistry & Molecular Biology

Cryo-EM reveals conformational flexibility in apo DNA polymerase ζ

Chloe Du Truong, Theodore A. Craig, Gaofeng Cui, Maria Victoria Botuyan, Rachel A. Serkasevich, Ka-Yi Chan, Georges Mer, Po-Lin Chiu, Rajiv Kumar

Summary: The study revealed that apo Pol zeta exhibits enhanced flexibility compared to its DNA-bound state, with concerted motions associated with expansion of the Pol zeta DNA-binding channel upon DNA binding. Additionally, a lysine residue obstructing the DNA-binding channel in apo Pol zeta was identified, suggesting a gating mechanism.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Article Multidisciplinary Sciences

Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation

Qi Hu, Maria Victoria Botuyan, Debiao Zhao, Gaofeng Cui, Elie Mer, Georges Mer

Summary: The BRCA1-BARD1 tumor suppressor complex plays a crucial role in DNA repair through homologous recombination. The complex is recruited to damaged chromatin and catalyzes ubiquitylation of histones, with BARD1's ankyrin repeat and BRCT domains binding to nucleosomal histones, DNA, and monoubiquitin attached to H2A. This mechanism involves a regulatory crosstalk between BRCA1-BARD1 and H2A, promoting ubiquitylation and opposing 53BP1 to promote homologous recombination.

NATURE (2021)

Article Cell Biology

53BP1-shieldin-dependent DSB processing in BRCA1-deficient cells requires CST-Polα-primase fill-in synthesis

Zachary Mirman, Nanda Kumar Sasi, Ashleigh King, J. Ross Chapman, Titia de Lange

Summary: The primary function of the shieldin complex in double-strand break repair in BRCA1-deficient cells is to recruit the CST-Pol alpha-primase complex for fill-in synthesis. The effectiveness of poly(ADP)-ribose polymerase 1 inhibition (PARPi) in BRCA1-deficient cells depends on 53BP1 and shieldin, which limit single-stranded DNA at double-strand breaks through blocking resection and/or fill-in by CST-Pol alpha-primase. CST-Pol alpha-primase promotes radial chromosome formation and BrdU incorporation at DSBs in PARPi-treated BRCA1-deficient cells, and shieldin acts primarily by recruiting CST for radial formation.

NATURE CELL BIOLOGY (2022)

Article Engineering, Biomedical

Anti-BCMA Immuno-NanoPET Radiotracers for Improved Detection of Multiple Myeloma

Eloise Thomas, Clelia Mathieu, Patricia Moreno-Gaona, Vincent Mittelheisser, Francois Lux, Olivier Tillement, Xavier Pivot, Paiman Peter Ghoroghchian, Alexandre Detappe

Summary: A novel PET-based anti-BCMA nanoplatform labeled with Cu-64 has shown improved sensitivity and specificity in monitoring minute plasma cell populations in the spine and femur compared to traditional immunoPET approaches in detecting tumor cells in MM patients. This immuno-nanoPET platform has the potential to enhance the management of MM patients when combined with tumor biopsy.

ADVANCED HEALTHCARE MATERIALS (2022)

Article Chemistry, Multidisciplinary

Optimal Physicochemical Properties of Antibody-Nanoparticle Conjugates for Improved Tumor Targeting

Vincent Mittelheisser, Pierre Coliat, Eric Moeglin, Lilian Goepp, Jacky G. Goetz, Loic J. Charbonniere, Xavier Pivot, Alexandre Detappe

Summary: Tumor-targeted antibody/fragment-conjugated nanoparticles show promise in improving local delivery of small molecules. A meta-analysis of 161 studies confirmed that targeted nanoparticles had significantly higher tumor uptake compared to naked nanoparticles. The study also found that the choice of nanoparticle type, size, and antibody moiety affected tumor uptake.

ADVANCED MATERIALS (2022)

Article Clinical Neurology

A novel missense HNRNPA1 variant in the PY-NLS domain in a patient with late-onset distal myopathy

Pitcha Chompoopong, Margherita Milone, Zhiyv Niu, Gaofeng Cui, Georges Mer, Teerin Liewluck

Summary: In this study, a novel variant in the HNRNPA1 gene was identified in a male patient with bilateral foot drop, expanding the phenotypic spectrum of hnRNPA1opathy.

NEUROMUSCULAR DISORDERS (2022)

Article Cell Biology

Human FACT subunits coordinate to catalyze both disassembly and reassembly of nucleosomes

Micah J. McCauley, Michael Morse, Nicole Becker, Qi Hu, Maria Victoria Botuyan, Emily Navarrete, Ran Huo, Uma M. Muthurajan, Ioulia Rouzina, Karolin Luger, Georges Mer, James Maher, Mark C. Williams

Summary: The histone chaperone FACT enhances transcription by targeting DNA-protein interactions. This study demonstrates the impact of FACT on nucleosome stability and dynamics, revealing contradictory functions of different FACT subdomains in nucleosome remodeling. These findings provide insights into the catalytic role of key FACT domains in nucleosome disassembly and reassembly.

CELL REPORTS (2022)

Editorial Material Chemistry, Multidisciplinary

A chemical strategy to study transient states in substrate ubiquitylation by cryo-EM

Qi Hu, Maria Victoria Botuyan, Georges Mer

Summary: The study presents a chemical trapping method to investigate short-lived intermediate states in substrate ubiquitylation. The effectiveness of this approach is demonstrated by determining single-particle cryo-EM structures related to nucleosome ubiquitylation.
Article Multidisciplinary Sciences

An autoinhibited state of 53BP1 revealed by small molecule antagonists and protein engineering

Gaofeng Cui, Maria Victoria Botuyan, Pascal Drane, Qi Hu, Benoit Bragantini, James R. Thompson, David J. Schuller, Alexandre Detappe, Michael T. Perfetti, Lindsey I. James, Stephen V. Frye, Dipanjan Chowdhury, Georges Mer

Summary: This study reveals an autoinhibited state of 53BP1 that hinders its ability to bind to chromatin. Small molecule ligands present a potential avenue for the development of cancer therapy drugs.

NATURE COMMUNICATIONS (2023)

Meeting Abstract Oncology

SENSITIZING POORLY DIFFERENTIATED THYROID CANCERS TO TSHR-CART CELL THERAPY WITH MEK INHIBITORS

John Copland, Kendall Schick, Justyna Gleba, Truc Huynh, James Miller, Erin MIller, Aylin Alasonyalilar Demirer, Erin Tapper, Reona Sakemura, Elizabeth Siegler, Michelle Cox, Carli Stewart, Ismail Can, Ekene Ogbodo, Claudia Manriquez Roman, Bezerra Evandro, Cui Gaofeng, Mer Georges, Olivier Gloria, Yushi Qui, Robert Smallridge, Abba Zubair, Han Tun, Saad Kenderian

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma

Xiangyu Zeng, Fei Zhao, Gaofeng Cui, Yong Zhang, Rajashree A. Deshpande, Yuping Chen, Min Deng, Jake A. Kloeber, Yu Shi, Qin Zhou, Chao Zhang, Jing Hou, Wootae Kim, Xinyi Tu, Yuanliang Yan, Zhijie Xu, Lifeng Chen, Huanyao Gao, Guijie Guo, Jiaqi Liu, Qian Zhu, Yueyu Cao, Jinzhou Huang, Zheming Wu, Shouhai Zhu, Ping Yin, Kuntian Luo, Georges Mer, Tanya T. Paull, Jian Yuan, Kaixiong Tao, Zhenkun Lou

Summary: This study reveals the potential role of METTL16 in the treatment of PDAC, particularly in cases with high METTL16 expression. Combining PARP inhibitors with gemcitabine may be an effective treatment strategy.

NATURE CANCER (2022)

No Data Available